GPCR Company Profile and Key Details

Q: Who are the executives of GPCR?

Dr. Raymond C. Stevens Ph.D.Chief Executive Officer & DirectorDr. Mark A. Bach M.D., Ph.D.Chief Medical OfficerMs. Lani IbarraSenior Vice President of Clinical Devel. OperationsDr. Fang Zhang Ph.D.Executive Vice President & Head of BiologyDr. Yingli Ma Ph.D.Chief Technology OfficerDr. Xichen Lin Ph.D.Chief Scientific OfficerMr. Tony PengSenior Vice President of LegalMs. Melita Sun JungChief Bus. OfficerMr. Jun S. YoonCo- Founder, Chief Financial Officer & Sec.Dr. Hui Lei Ph.D.Senior Vice President of Chemistry

NASDAQ : GPCR

Structure Therapeutics

$51.89

-4.26-7.59%

At Close 4:00 PM

59.54

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Structure Therapeutics Inc. (GPCR) stock declined over -7.59%, trading at $51.89 on NASDAQ, down from the previous close of $56.15. The stock opened at $54.29, fluctuating between $51.14 and $55.47 in the recent session.

Stock Snapshot

56.15

Prev. Close

2.99B

Market Cap

51.14

Day Low

-20.51

P/E Ratio

-2.53

EPS (TTM)

-1.76

Cash Flow per Share

54.29

Open

57.57M

Number of Shares

55.47

Day High

95.06%

Free Float in %

9.76

Book Value

1.27M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 18, 2026	55.47	55.47	51.14	51.89	1.27M
Mar 17, 2026	56.06	57.47	53.60	56.15	1.05M
Mar 16, 2026	56.58	61.20	53.06	56.65	3.19M
Mar 13, 2026	55.00	56.00	52.51	53.75	587.07K
Mar 12, 2026	57.46	57.65	54.58	54.58	448.17K
Mar 11, 2026	58.22	59.55	57.33	58.20	695.95K
Mar 10, 2026	56.95	60.61	56.95	58.22	932.49K
Mar 09, 2026	56.85	58.88	55.00	56.50	882.73K
Mar 06, 2026	57.90	59.31	57.02	57.73	820.15K
Mar 03, 2026	62.19	64.64	59.56	63.04	1.18M
Mar 02, 2026	61.88	64.37	61.51	62.90	502.27K
Feb 27, 2026	64.13	65.05	62.17	62.98	711.6K
Feb 26, 2026	66.24	66.25	63.07	64.75	928.66K
Feb 25, 2026	69.00	69.00	66.40	66.53	455.17K
Feb 24, 2026	67.12	68.96	64.83	68.91	769.7K
Feb 23, 2026	67.78	68.26	66.16	67.12	793.18K
Feb 20, 2026	67.11	68.14	65.58	66.55	927.07K
Feb 19, 2026	68.23	68.23	64.96	67.47	726.93K
Feb 18, 2026	71.23	71.70	68.20	68.36	1.02M
Feb 17, 2026	69.61	72.31	68.65	71.41	1M

Contact Details

South San Francisco, CA 94080

United States

https://structuretx.com 628 229 9277

About Company

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Stock Peers

REGN

-14.93-1.97%

Regeneron Pharmaceuticals, Inc.$744.12 ARGX

-21.26-3.01%

argenx SE$684.77 UTHR

-9.67-1.79%

United Therapeutics Corporation$530.35 VRTX

-10.9-2.36%

Vertex Pharmaceuticals Incorporated$451.59 MDGL

-1.18-0.27%

Madrigal Pharmaceuticals, Inc.$442.00 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-5.62-1.75%

Alnylam Pharmaceuticals, Inc.$314.80 PRAX

-14.59-4.81%

Praxis Precision Medicines, Inc.$288.79 KRYS

-5.5-2.15%

Krystal Biotech, Inc.$250.83 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Structure Therapeutics Inc. (NASDAQ:GPCR) closed at $51.89 USD, losing -$4.26 (-7.59%) from the previous close of $56.15. The stock is currently mid-range between its 52-week high and low $13.22 and $94.90. With a market capitalization of about $2.99 billion, Structure Therapeutics Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~-1.90). Key stats such as the average daily volume over the past year has been around 1.05 million shares, in line with its 52-week average. Headquartered in South San Francisco, CA, Structure Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Raymond C. Stevens, the company employs approximately 163 people and listed since February 03, 2023. Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs.

Technical Performance

GPCR has shown sold momentum, gaining 31.23% over the past week and 232.43% over the past quarter, though year-to-date performance is up 30.87%. Short-term trend indicators are bearishly aligned (SMA20 -13.39%, SMA50 -13.04%, SMA200 70.71%). The stock’s 14-day RSI is 35.57 (weak momentum), while the ATR of 4.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -31.77% below its high and over 389.79% above its low. Average 10-day trading volume of 1.13 million shares is in line with the 3-month average of 1.04 million, indicating normal recent market interest.

Valuation Metrics

Structure Therapeutics Inc. trades at a P/E ratio of -21.78, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.03 suggesting the stock is closer to book value. The P/FCF stands at -13.24, also below market averages.

Dividend & Fair Value

Structure Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $13.40. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Structure Therapeutics Inc. generated EPS of -$3.65 over the past year. Five-year average earnings growth is -51.75%. The latest quarter delivered EPS of -$0.37. The next quarter is forecast at -$0.37. Next year's EPS is expected at -$14.74. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $140.00 to $60.00. The high target offers 169.8% upside. The low target suggests 15.63% downside. The mean target is $101.12. This offers 94.87% upside. Structure Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 2.78%. The prior quarter beat by 28.57%. Over the last six quarters, Apple has recorded several small beats. These include -21.74% in August 08, 2024.

Shareholding & Insider Activity

Structure Therapeutics Inc. has 57.60 million shares outstanding. The public float is 133.55 million shares, elevated short interest at 18.01% of float. This equals 7.19 million shares. The short ratio is 10.2 days. Institutional investors hold 101.3% of the float. Insiders own 3.04%. Farid Ramy holds 275.00 thousand shares, FMR LLC has 4.10 thousand shares and Stevens Raymond C has 0.00 shares. Over the past six months, insider transactions show net selling. They sold 15.56 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Structure Therapeutics has not generated any revenue. Returns are negative, with ROA at -18.58% and ROE at -19.77%.
On valuation metrics, Structure Therapeutics trades at a P/E of -21.78, P/S of 0.00 and P/B of 2.03. The current ratio is 24.81 and quick ratio is 24.81. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -34.25.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Structure Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $949.17K (margin 0.00%). Operating income was - $102.69M (margin 0.0%). Net income was- $89.54M (EPS - $2.44).
The company ended the quarter with $467.32M in cash and short-term investments, a total debt of $5.45M, and net debt of - $124.34M. Total assets were $482.02M, with equity of $452.97M. Financials further reflected weakness, with operating cash flow of - $79.42M, free cash flow of - $81.58M, and capital expenditures of - $2.17M.

Price Forecast & Outlook

Our AI price prediction model suggests that Structure Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.56%, with price expected at $46.93 by March 31, 2026, within a range of $44.59 to $49.32 3-Month Outlook: Projected rise of 85.22%, reaching $96.11 by June 15, 2026, with a range of $94.83 to $97.16. 1-Year Outlook: Projected gain of 21.58%, with price at $63.09 by March 17, 2027, within a range of $57.87 to $69.00.

Key Takeaways

Structure Therapeutics Inc. (NASDAQ:GPCR) shares are up 30.87% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Structure Therapeutics Inc. trading at a premium to the broader market with a P/E of -21.78. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $86.33, suggesting 66.37% upside. Our AI forecast model points to short-term weakness (-9.56% over two weeks), a medium-term rise (85.22% over three months), and a longer-term gain (21.58% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Structure Therapeutics Inc. (GPCR) stock price?

Structure Therapeutics Inc. (NASDAQ: GPCR) stock price is $51.89 in the last trading session. During the trading session, GPCR stock reached the peak price of $55.47 while $51.14 was the lowest point it dropped to. The percentage change in GPCR stock occurred in the recent session was -7.59% while the dollar amount for the price change in GPCR stock was - $4.26.

GPCR's industry and sector of operation?

The NASDAQ listed GPCR is part of Biotechnology industry that operates in the broader Healthcare sector. Structure Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GPCR?

Dr. Raymond C. Stevens Ph.D.
Chief Executive Officer & Director
Dr. Mark A. Bach M.D., Ph.D.
Chief Medical Officer
Ms. Lani Ibarra
Senior Vice President of Clinical Devel. Operations
Dr. Fang Zhang Ph.D.
Executive Vice President & Head of Biology
Dr. Yingli Ma Ph.D.
Chief Technology Officer
Dr. Xichen Lin Ph.D.
Chief Scientific Officer
Mr. Tony Peng
Senior Vice President of Legal
Ms. Melita Sun Jung
Chief Bus. Officer
Mr. Jun S. Yoon
Co- Founder, Chief Financial Officer & Sec.
Dr. Hui Lei Ph.D.
Senior Vice President of Chemistry

How GPCR did perform over past 52-week?

GPCR's closing price is 292.51% higher than its 52-week low of $13.22 where as its distance from 52-week high of $94.90 is -45.32%.

How many employees does GPCR have?

Number of GPCR employees currently stands at 163.

Link for GPCR official website?

Official Website of GPCR is: https://structuretx.com

How do I contact GPCR?

GPCR could be contacted at phone 628 229 9277 and can also be accessed through its website. GPCR operates from 611 Gateway Boulevard, South San Francisco, CA 94080, United States.

How many shares of GPCR are traded daily?

GPCR stock volume for the day was 1.27M shares. The average number of GPCR shares traded daily for last 3 months was 1.05M.

What is the market cap of GPCR currently?

The market value of GPCR currently stands at $2.99B with its latest stock price at $51.89 and 57.57M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	163
Beta	-1.9
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

GPCR Company Profile and Key Details

Structure Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways